GlaxoSmithKline Says FDA Rejected Zofran Birth Defects

By Alison Noon · July 20, 2018, 4:00 PM EDT

GlaxoSmithKline argued Thursday that it cannot be held liable for birth defects caused after pregnant women were prescribed its postoperative nausea drug Zofran because the U.S. Food and Drug Administration has...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

In Re: Zofran (Ondansetron)Products Liability Litigation

Case Number

Court

Massachusetts

Nature of Suit

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Date Filed

October 13, 2015

Recent Articles By Alison

April 30, 2019
With Opioid Charges, DOJ Signals Compliance Fixation
April 11, 2019
Trump Admin Moves To Rein In Agency Guidance Materials
March 22, 2019
Medtronic Warning Highlights Debate On FDA Cyber Policy
January 16, 2019
Outcome Health Adds Compliance Chief After Fraud Claims
December 20, 2018
FDA Tells Stem Cell Cos. Regulatory Eyes Fixed On Them
October 05, 2018
Tobacco Warning Labels Ready By 2021 At Earliest, FDA Says
October 02, 2018
Ex-Abbott Researcher Says 'Erroneous' Law Sank FCA Claims
September 20, 2018
2nd Circuit Balks At Bid To Lower No-Fault Fraud Sentence
September 19, 2018
Mass. Doc Dodges Prison After Giving Patient Info To Drug Co.
September 18, 2018
Mass. Hospital Rips FCA Claims Med Students Not Supervised